PLD-301, a phosphate prodrug of clopidogrel thiolactone discovered by Prelude Pharmaceuticals with desire to to overcome clopidogrel level of resistance, was evaluated because of its inhibitory influence on ADP-induced platelet aggregation in rats. may have some advantages more than clopidogrel, such as for example overcoming clopidogrel level of resistance for CYP2C19-allele loss-of-function service providers, and… Continue reading PLD-301, a phosphate prodrug of clopidogrel thiolactone discovered by Prelude Pharmaceuticals